Cancer specific deaths number | Controls number | OR (95% CI) | P | OR (95% CI) | P | |
---|---|---|---|---|---|---|
ACEI user versus non user | ARB user versus non user | |||||
Colorectal cancer | ||||||
Main analysis: diagnosis to six months prior to deatha | 1,093 | 5,231 | 0.76 (0.62, 0.93) | 0.01 | 0.80 (0.59, 1.09) | 0.16 |
Diagnosis to one year prior to deathb | 869 | 4,152 | 0.83 (0.67, 1.03) | 0.10 | 0.89 (0.64, 1.25) | 0.51 |
Restricted to users of any antihypertensive medicationc prior to cancer diagnosisd | 427 | 1,934 | 0.83 (0.65, 1.07) | 0.15 | 0.90 (0.63, 1.27) | 0.54 |
Comparison group restricted to users of any antihypertensive in exposure periodc | 596 | 1,845 | 0.75 (0.61, 0.92) | 0.01 | 0.80 (0.59, 1.10) | 0.16 |
Additionally adjusting for other antihypertensivese | 1,093 | 5,231 | 0.75 (0.61, 0.92) | 0.01 | 0.80 (0.59, 1.09) | 0.16 |
≥730 DDDs versus 0 DDDs (non-user) | 1,093 | 5,231 | 0.73 (0.62, 1.00) | 0.03 | 0.93 (0.64, 1.36) | 0.72 |
Stage 1 and 2f | 328 | 1,483 | 0.54 (0.38, 0.77) | 0.001 | 0.80 (0.47, 1.37) | 0.41 |
Stage 3 and 4f | 740 | 3,185 | 0.86 (0.68, 1.10) | 0.23 | 1.05 (0.72, 1.55) | 0.79 |
Colon | 649 | 3,134 | 0.84 (0.64, 1.09) | 0.19 | 0.77 (0.52, 1.15) | 0.21 |
Rectal | 444 | 2,097 | 0.67 (0.49, 0.92) | 0.01 | 0.91 (0.56, 1.50) | 0.72 |
Males | 638 | 3,078 | 0.80 (0.62, 1.03) | 0.08 | 0.93 (0.62, 1.41) | 0.74 |
Females | 455 | 2,153 | 0.70 (0.49, 0.98) | 0.04 | 0.64 (0.40, 1.03) | 0.06 |
Pre-diagnostic useg | 1,641 | 7,815 | 1.06 (0.89, 1.27) | 0.51 | 0.86 (0.62, 1.18) | 0.35 |
Time varying covariate analysish | 1,109 | 2,559 | ||||
≥1 DDDs versus 0 DDDs (non-user) | 0.81 (0.69, 0.96) | 0.01 | 0.86 (0.66, 1.12) | 0.26 | ||
1 to365 DDDs versus 0 DDDs (non-user) | 0.76 (0.59, 0.97) | 0.03 | 0.64 (0.40, 1.03) | 0.07 | ||
≥365 DDDs versus 0 DDDs (non-user) | 0.85 (0.69, 1.03) | 0.10 | 1.00 (0.73, 1.38) | 0.99 | ||
≥1 DDDs versus 0 DDDs (non-user) in stage 1 and 2 patients | 0.62 (0.46, 0.84) | 0.002 | 0.65 (0.41, 1.05) | 0.08 | ||
≥1 DDDs versus 0 DDDs (non-user) in stage 3 and 4 patients | 0.91 (0.74, 1.10) | 0.33 | 0.97 (0.70, 1.34) | 0.83 |